NASDAQ: CBUSCibus Inc Stock
$18.22-0.53 (-2.83%)
Updated Sep 29, 2023
CBUS Price
$18.22
Fair Value Price
N/A
Market Cap
$387.80M
52 Week Low
$6.25
52 Week High
$38.85
P/E
-1.01x
P/B
0.8x
P/S
199.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$323.00k
Earnings
-$32.87M
Gross Margin
100%
Operating Margin
-9,373.99%
Profit Margin
-10,176.8%
Debt to Equity
0.4
Operating Cash Flow
-$22M
Beta
1.13
Next Earnings
Nov 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A
CBUS Overview
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CBUS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CBUS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CBUS is good value based on its book value relative to its share price (0.8x), compared to the US Biotechnology industry average (5.09x)
P/B vs Industry Valuation
CBUS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CBUS due diligence checks available for Premium users.
Be the first to know about important CBUS news, forecast changes, insider trades & much more!
CBUS News
Valuation
CBUS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.01x
Industry
13.67x
Market
12.37x
CBUS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.8x
Industry
5.09x
CBUS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CBUS's financial health
Profit margin
Revenue
$197.0k
Net Income
-$18.7M
Profit Margin
-9,487.3%
CBUS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CBUS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$814.3M
Liabilities
$193.1M
Debt to equity
0.4
CBUS's short-term assets ($54.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CBUS's long-term liabilities ($170.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CBUS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CBUS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.7M
Investing
$58.8M
Financing
$1.8M
CBUS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CBUS vs Biotech Stocks
Cibus Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.